Abstract
ABCB1 overexpression is known to contribute to multidrug resistance (MDR) in cancers. Therefore, it is critical to find effective drugs to target ABCB1 and overcome MDR. Erdafitinib is a tyrosine kinase inhibitor (TKI) of fibroblast growth factor receptor (FGFR) that is approved by the FDA to treat urothelial carcinoma. Previous studies have demonstrated that some TKIs exhibit MDR reversal effect. In this work, we examined whether erdafitinib could reverse MDR mediated by ABCB1. The results of reversal experiments showed that erdafitinib remarkably reversed ABCB1-mediated MDR without affecting ABCG2-mediated MDR. The results of immunofluorescence and Western blot analysis demonstrated that erdafitinib did not affect the expression of ABCB1 or its cellular localization. Further study revealed that erdafitinib inhibited ABCB1 efflux function leading to increasing intracellular drug accumulation, thereby reversing MDR. Furthermore, ATPase assay indicated that erdafitinib activated the ABCB1 ATPase activity. Docking study suggested that erdafitinib interacted with ABCB1 on the drug-binding sites. In summary, this study demonstrated that erdafitinib can reverse MDR mediated by ABCB1, suggesting that combination of erdafitinib and ABCB1-substrate conventional chemotherapeutic drugs could potentially be used to overcome MDR mediated by ABCB1.
Highlights
Multidrug resistance (MDR) is one of the main reasons leading to failure of chemotherapy in cancers [1, 2]
The present study evaluates if erdafitinib could reverse multidrug resistance (MDR) mediated by ABCB1 in drug resistant cancer cells
The reversal effect of erdafitinib was assessed in ABCB1-transfected cells
Summary
Multidrug resistance (MDR) is one of the main reasons leading to failure of chemotherapy in cancers [1, 2]. ATP-binding cassette (ABC) transporters-mediated drug resistance is one of the most important factor causing MDR in cancer [7]. There is no single drug which is approved by the FDA as a reversal agent for overcoming MDR mediated by ABC transporters. Erdafitinib (Figure 1A) is a TKI which affect the fibroblast growth factor receptor (FGFR) to inhibit the tyrosine kinase activities of FGFR1-4 [24]. It is the first FGFR kinase inhibitor approved by the FDA in 2019 to treat urothelial carcinoma. The present study evaluates if erdafitinib could reverse MDR mediated by ABCB1 in drug resistant cancer cells
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
